FDA Approves Lisraya as First Oral Therapy for Dermatomyositis

Companies: Roivant Sciences / Priovant Therapeutics · Drug: Lisraya (brepocitinib) · Indication: Adult Dermatomyositis · Regulatory Action: FDA Approval · Date: August 27, 2026 Summary The FDA approved Priovant Therapeutics’ Lisraya (brepocitinib), a once-daily oral TYK2/JAK1 inhibitor, for adult dermatomyositis, making it the first oral,…